Press Release

20 Jul Braeburn and Camurus Announce Submission for CAM2038 for Opioid Use Disorder

Posted at 15:29h in Press Release

Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use DisorderIf approved, CAM2038 would provide...

12 Jul Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain

Posted at 15:22h in Press Release

Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic PainLund, Sweden...

22 Jun Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms

Posted at 15:04h in Press Release

Phase 2 Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use DisorderNew data...

13 Jun Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE® in Canada

Posted at 19:39h in Press Release

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug DependencePRINCETON, N.J....

05 Jun Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO

Posted at 17:02h in Press Release

Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO, former Head of CNS and Pain Therapeutics for Teva PharmaceuticalsBraeburn President...

02 May Braeburn and Camurus Announce Positive Top-line Results from CAM2038 Safety Study

Posted at 19:39h in Press Release

Princeton, New Jersey and Lund, Sweden — 2 May 2017 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced...

Define the future at Braeburn...together.

Join Our Team